After three clinical trials, Novartis is positive about the lung drug to hit the market soon. The drug has been designed for patients suffering from chronic obstructive pulmonary disease (COPD), often known as smokers' cough.
The drug, QVA149, is the combination of Novartis' Onbrez and its other lung drug NVA237. Till now, the company has carried three clinical trials, which have showed positive results for the new drug. The three trials were a part of the 10 trials involved in total. The total analysis is expected to complete by 2012.
The first trial proved that the drug alone showed better results than combined results of both Onbrez and NVA237. The second trial of the drug showed that the patients were able to develop patience to suffer. Moreover, the third trial proved that it was equivalent to its competitors in case of tolerability and safety.
The company has high hopes with this drug. It is expecting that the drug will be able to let the company to take on market leader GlaxoSmithKline.
Kepler Capital Markets analyst Martin Voegtli, said “We model $2.9 billion peak sales by 2020 for QVA149, which is expected to form the most important portfolio addition over the next few years. Filing in Europe is expected by year-end 2012”.
- Fireball over Yellowknife Turns the Night-Sky Bright
- Bitcoin investors call for protection after collapse of two major Bitcoin platforms
- Digitally-connected young Canadians are regular targets of ‘phishing’ scams
- Comprehensive Study Casts Doubt on Value of Mammograms
- Individuals have to stop piglet-killing disease by keeping it out of their barns